Influence of growth hormone on circulating fibroblast growth factor 21 levels in humans

Journal of Internal Medicine

Volumn 274, Issue 3, 2013, Pages 227-232

  Lundberg, J ^a   Hoybye C ^a   Krusenstjerna Hafstrom T ^b   Bina, H A ^c   Kharitonenkov, A ^c   Angelin, B ^a   Rudling, M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

FGF21; GH; NEFA; Oral glucose test

Indexed keywords

FATTY ACID; FIBROBLAST GROWTH FACTOR 21; HUMAN GROWTH HORMONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; TREATMENT RESPONSE;

FGF21; GH; NEFA; ORAL GLUCOSE TEST;

ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ACIDS, NONESTERIFIED; FEMALE; FIBROBLAST GROWTH FACTORS; HUMAN GROWTH HORMONE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; RADIOIMMUNOASSAY;

EID: 84881556372     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12112     Document Type: Article

References (20)

1. Angelin B, Larsson TE, Rudling M. Circulating fibroblast growth factors as metabolic regulators-a critical appraisal. Cell Metab 2012; 16: 693-705.
2. Kharitonenkov A, Shiyanova TL, Koester A et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115: 1627-1635.
3. Kharitonenkov A, Wroblewski VJ, Koester A et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007; 148: 774-781.
4. Xu J, Lloyd DJ, Hale C et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58: 250-259.
5. Coskun T, Bina HA, Schneider MA et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008; 149: 6018-6027.
6. Inagaki T, Dutchak P, Zhao G et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007; 5: 415-425.
7. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007; 5: 426-437.
8. Galman C, Lundasen T, Kharitonenkov A et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 2008; 8: 169-174.
9. Chen W, Hoo RL, Konishi M et al. Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes. J Biol Chem 2011; 286: 34559-34566.
10. Yu J, Zhao L, Wang A et al. Growth hormone stimulates transcription of the fibroblast growth factor 21 gene in the liver through the signal transducer and activator of transcription 5. Endocrinology 2012; 153: 750-758.
11. Barclay JL, Nelson CN, Ishikawa M et al. GH-dependent STAT5 signaling plays an important role in hepatic lipid metabolism. Endocrinology 2011; 152: 181-192.
12. Hilding A, Hall K, Wivall-Helleryd IL, Saaf M, Melin AL, Thoren M. Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19-82 years, in relation to those in healthy subjects. J Clin Endocrinol Metab 1999; 84: 2013-2019.
13. Krusenstjerna-Hafstrom T, Madsen M, Vendelbo MH et al. Insulin and GH signaling in human skeletal muscle in vivo following exogenous GH exposure: impact of an oral glucose load. PLoS ONE 2011; 6: e19392.
14. Lind S, Rudling M, Ericsson S et al. Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans. Arterioscler Thromb Vasc Biol 2004; 24: 349-356.
15. Gotherstrom G, Bengtsson BA, Bosaeus I, Johannsson G, Svensson J. A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. J Clin Endocrinol Metab 2007; 92: 1442-1445.
16. Persson L, Henriksson P, Westerlund E, Hovatta O, Angelin B, Rudling M. Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp(a) or bile acid synthesis in women. Arterioscler Thromb Vasc Biol 2012; 32: 810-814.
17. Lin Z, Gong Q, Wu C et al. Dynamic Change of Serum FGF21 Levels in Response to Glucose Challenge in Human. J Clin Endocrinol Metab 2012; 97: E1224-E1228.
18. Lundasen T, Hunt MC, Nilsson LM et al. PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun 2007; 360: 437-440.
19. Yu H, Xia F, Lam KS et al. Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. Clin Chem 2011; 57: 691-700.
20. Inagaki T, Lin VY, Goetz R, Mohammadi M, Mangelsdorf DJ, Kliewer SA. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab 2008; 8: 77-83.